Chuang Wen-Yu, Chang Hung, Chang Gwo-Jyh, Wang Tzu-Hao, Chang Yu-Sun, Wang Tong-Hong, Yeh Chi-Ju, Ueng Shir-Hwa, Chien Hui-Ping, Chang Chiu-Yueh, Wan Yung-Liang, Hsueh Chuen
Department of Pathology, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan.
Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Histopathology. 2017 May;70(6):986-999. doi: 10.1111/his.13161. Epub 2017 Mar 10.
To characterize the clinicopathological and genetic features of pleomorphic mantle cell lymphoma (PMCL), which morphologically mimics diffuse large B cell lymphoma (DLBCL).
We screened systematically 500 B cell lymphomas morphologically compatible with DLBCL using an immunohistochemical algorithm of three markers (CD5, cyclin D1 and SOX11). Ten cases of PMCL were identified for further study and, surprisingly, four (40%) of them were cyclin D1-negative. These 10 patients were mainly elderly males with advanced disease, and their median survival was only 11 months. All cyclin D1-positive PMCLs tested showed an IGH-CCND1 translocation, whereas one of the four cyclin D1-negative PMCLs had a translocation involving CCND2 and a high CCND2 mRNA level (P < 0.000001). The genomewide copy number profiles of both cyclin D1-positive and cyclin D1-negative PMCLs were similar to those of classical mantle cell lymphoma (MCL) reported previously, confirming the diagnosis. Secondary genetic alterations involved in oncogenic pathways of MCL were observed more frequently in these PMCLs, possibly decreasing the dependence on the driving CCND1 translocation and accounting for the common cyclin D1 negativity. Copy number gains of PIK3CA and CCDC50 were detected in all cyclin D1-negative PMCLs but in only 40% of the cyclin D1-positive PMCLs. These additional oncogenic signals may compensate for the common absence of CCND2 translocation in cyclin D1-negative PMCL.
We demonstrate for the first time that cyclin D1 negativity is surprisingly common in PMCL morphologically mimicking DLBCL, and the use of a simple immunohistochemical algorithm can prevent misclassification and inappropriate treatment.
描述多形性套细胞淋巴瘤(PMCL)的临床病理和基因特征,其在形态学上类似于弥漫性大B细胞淋巴瘤(DLBCL)。
我们使用三种标志物(CD5、细胞周期蛋白D1和SOX11)的免疫组织化学算法,系统筛选了500例形态学上与DLBCL相符的B细胞淋巴瘤。确定了10例PMCL进行进一步研究,令人惊讶的是,其中4例(40%)细胞周期蛋白D1呈阴性。这10例患者主要为老年男性,疾病处于晚期,中位生存期仅11个月。所有检测的细胞周期蛋白D1阳性的PMCL均显示IGH-CCND1易位,而4例细胞周期蛋白D1阴性的PMCL中有1例存在涉及CCND2的易位且CCND2 mRNA水平较高(P<0.000001)。细胞周期蛋白D1阳性和阴性的PMCL的全基因组拷贝数图谱与先前报道的经典套细胞淋巴瘤(MCL)相似,从而证实了诊断。在这些PMCL中更频繁地观察到涉及MCL致癌途径的继发性基因改变,这可能降低了对驱动性CCND1易位的依赖性,并解释了常见的细胞周期蛋白D1阴性。在所有细胞周期蛋白D1阴性的PMCL中均检测到PIK3CA和CCDC50的拷贝数增加,但在仅40%的细胞周期蛋白D1阳性的PMCL中检测到。这些额外的致癌信号可能弥补了细胞周期蛋白D1阴性的PMCL中常见的CCND2易位缺失。
我们首次证明,在形态学上模仿DLBCL的PMCL中,细胞周期蛋白D1阴性出奇地常见,使用简单的免疫组织化学算法可防止误诊和不恰当的治疗。